Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 3401 - 3408 of 12093 results
E-Verify Records Purge Scheduled for May 14, 2021
February 25, 2021| Alert| Viewpoint
Doctrine of Assignor Estoppel to be Reviewed by U.S. Supreme Court
February 25, 2021| Blog| Viewpoint
Design Patent Registrations after Brexit and Updates to Design Rights in China
February 25, 2021| Blog| Viewpoint
President Biden Lifts Order Suspending Entry of New Immigrants
February 25, 2021| Alert| Viewpoint
Supreme Court Declines to Weigh in on Requiring Objective Falsity in FCA Medical Necessity Cases
February 24, 2021| Blog| Viewpoint
Webinar Recording: Health Care Enforcement Year in Review & 2021 Outlook
February 24, 2021| News
Fourth Circuit Affirms District Court’s First-of-Its-Kind Divestiture Order in Private Merger Challenge
February 23, 2021| Blog| Viewpoint
Mintz Atty On Steering Quantum-Si's $1.46B Go-Public Deal
February 23, 2021| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|